Abraham Ceesay is CEO at Rapport Therapeutics, Inc. (RAPP). They have made 5 open-market trades across 2 companies since 2022, most recently 2026-09-23.
CIK 0001722140
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RAPP | 456,767 | $12.6M |
| CERE | 19,210 | $864K |
| CRL | 2,384 | $716K |
| PCRX | 9,039 | $329K |
| Total | $14.5M |
Shares reported on the most recent Form 4, priced at the 2026-09-24 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RAPP | SELL · 10b5-1 | 2026-09-23 | 2026-09-24 | $39.17 | $87K | -8.4% | — | — |
| RAPP | SELL · 10b5-1 | 2026-09-08 | 2026-09-09 | $45.61 | $374K | -8.0% | -28.8% | — |
| RAPP | SELL · 10b5-1 | 2026-08-25 | 2026-08-26 | $49.57 | $938K | -11.4% | -34.7% | — |
| RAPP | SELL · 10b5-1 | 2026-08-10 | 2026-08-12 | $47.25 | $2.4M | +1.9% | -10.5% | — |
| RAPP | SELL · 10b5-1 | 2026-07-27 | 2026-07-29 | $42.11 | $93K | +11.6% | +15.9% | — |
| RAPP | SELL · 10b5-1 | 2026-07-14 | 2026-07-15 | $40.00 | $328K | +5.4% | +18.2% | -27.5% |
| RAPP | SELL · 10b5-1 | 2026-06-29 | 2026-07-01 | $39.83 | $327K | +2.7% | +2.0% | -17.9% |
| RAPP | SELL | 2026-02-18 | 2026-02-19 | $29.35 | $320K | -6.2% | -6.0% | +20.5% |
| RAPP | SELL · 10b5-1 | 2026-01-20 | 2026-01-22 | $26.12 | $285K | -1.4% | +8.3% | +32.2% |
| RAPP | SELL · 10b5-1 | 2025-12-17 | 2025-12-18 | $29.56 | $612K | +2.7% | -12.1% | -10.4% |
| RAPP | SELL · 10b5-1 | 2025-11-17 | 2025-11-18 | $25.20 | $550K | +10.3% | +14.5% | +12.2% |
| RAPP | SELL · 10b5-1 | 2025-10-15 | 2025-10-16 | $25.78 | $401K | +18.1% | +2.4% | +11.8% |
| RAPP | SELL · 10b5-1 | 2025-09-17 | 2025-09-19 | $26.31 | $4.0M | +9.2% | +0.7% | +12.9% |
| PCRX | SELL · 10b5-1 | 2025-09-04 | 2025-09-08 | $27.19 | $128K | -0.0% | -12.2% | -8.4% |
| CERE | SELL | 2022-09-08 | 2022-09-12 | $32.50 | $624K | -13.7% | -12.1% | -11.7% |
| CERE | SELL | 2022-08-22 | 2022-08-24 | $32.50 | $624K | -12.7% | -20.9% | -12.2% |
| CERE | SELL | 2022-08-15 | 2022-08-17 | $34.12 | $656K | -5.0% | -11.8% | -8.7% |
| CERE | SELL | 2022-08-05 | 2022-08-09 | $35.56 | $2.7M | -18.6% | -19.9% | -32.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.